In late October, the HOLVES technical team split into two groups: one at the Xiamen International Expo Center for the 68th CIPM Pharmaceutical Machinery Expo, and the other in Shenzhen for the 3rd Algae Synthetic Biology and Biomanufacturing Innovation Forum.

From traditional pharmaceuticals to algae synthetic biology, the two tracks appear quite different, but they point to the same core question: how can a process that works in the laboratory cross the scale-up gap and remain reliable in pilot and production?
HOLVES’ answer is no longer just individual instruments, but a complete technology chain—from front-end screening to process scale-up and then to data analytics.
 

At the CIPM, HOLVES focused on a systematic breakdown of the process chain from screening to pilot-scale scale-up.
The MatrixH PBR high-throughput parallel bioreactor, making its first appearance at an industry exhibition, together with the MatrixH high-throughput screening platform, became the center of technical discussion. It turns front-end screening into “parallel computing”—supporting flexible configurations of 8 to 64 reaction units, with independent control of pH, DO, temperature, and other parameters. This eliminates repeated trial and error between shake flasks and single bioreactors, greatly improving process development efficiency and data traceability.
 

For pilot and downstream stages, the Eu210 laboratory advanced fermenter brings control precision to an industrial level; the OmniCell510 stainless-steel bioreactor uses a highly integrated GMP-compliant four-valve group system to make aseptic switching traceable; and the K2T-Pilot pilot-scale automated ultrafiltration system reliably handles purification and collection.
 

 
 

If Xiamen demonstrated industrial-scale scale-up capability, the Shenzhen forum directly addressed the demanding pain points of algae and photosynthetic microorganism cultivation: extremely high requirements for light and shear force, and extremely precious early-stage samples.
 

In response, HOLVES did not stack up novel concepts in Shenzhen. Instead, it brought classic laboratory-scale solutions proven in the market, sending a clear signal to the industry: mature small-scale and micro-purification solutions can also be smoothly transferred to photosynthetic biomanufacturing. The stable control logic honed over many years in traditional fermentation and biopharmaceuticals is exactly the foundation for algae synthetic biology to move from the laboratory to industrialization. Every large scale begins with precise early-stage control.
 

Hardware forms the skeleton of a process, but in real R&D and production scenarios, the most troublesome issue is often data scattered across different locations. This is the core motivation behind two new technologies released by HOLVES: Nexus Insight and Factor Scope.
Nexus Insight acts as a “data hub,” horizontally connecting different equipment such as fermentation, purification, and ultrafiltration systems. It maps historical trends and batch information into a unified view and turns them into traceable process assets.
Factor Scope is deep process analytics software. When photosynthetic efficiency hits a bottleneck or scale-up yield declines, it uses DoE, statistical modeling, and machine learning to identify key features from complex parameters and build interpretable process models—reducing blind trial and error.
Equipment is the carrier of the process; software is the guide. At this exhibition, HOLVES did not aim to display a seemingly perfect system, but to reduce the unknown variables in real production lines and laboratories during process scale-up.
After all, every step forward in biomanufacturing has never relied on impressive booths, but on every precise data record and every stably operating batch.